Gsk Share Discussion Threads

[essentialinvestor] 25/10/2017 12:20

Had a quick look and unless I'm misreading, FCF looks on the weak side.
So much detail very difficult to form a view quickly, at least for me!.

[zho] 25/10/2017 12:02

Q3 results out:

Emma Walmsley, Chief Executive Officer, GSK said:
"Performance in the quarter showed continued progress
with sales growth and improved operating margins.
This was driven by targeted cost savings and restructuring
and integration benefits, which particularly benefited
Vaccines and Consumer Healthcare, and also supported
investment in our new products and R&D pipeline.
Adjusted earnings per share for Q3 were 32.5p and
we remain on course for our full-year earnings guidance,
with cash generation continuing to improve. We are
also pleased that we have secured major approvals
for Trelegy Ellipta in COPD and Shingrix, our shingles
vaccine."

[tompion] 25/10/2017 10:11

I also had Zostavax recently which isn't as good - a lower percentage of vaccinated individuals are protected by Zostavax compared to Shingrix.

[zingaro] 25/10/2017 09:46

Well, my NHS (Wales) shingles jab was Zostavax by Sanofi. Sorry !

[zingaro] 23/10/2017 17:59

2hog - I will ask on Wednesday when I get mine.

[2hoggy] 23/10/2017 17:43

Is that shingles drug the one that the nhs uses now,you have to be 70 to get it as I enquired recently??

[city chappy] 23/10/2017 16:17

GSK should definitely be looking at buying Immupharma's lupus drug Lupuzor which finishes Phase 3 in Jan 2018 and seems set to wipe out GSKs lupus drug Benlysta on price, efficacy and safety.

[philanderer] 23/10/2017 13:35

NICE nod for GSK’s ‘bubble baby syndrome’ gene therapy

[philanderer] 20/10/2017 23:56

Nice :-)


“We are absolutely thrilled to get to this point because the science behind this vaccine offers tremendous potential for helping patients, protecting them against getting shingles and its complications,” said Dr. Leonard Friedland, vice president for scientific affairs and public health for GSK’s North American vaccines unit.

GSK has been keenly awaiting the FDA’s ruling, eager to get to market a vaccine analysts estimate could reach $1 billion a year in sales by 2022

[romeike] 20/10/2017 23:51

Shingrix approved by FDA

[jadeticl3] 20/10/2017 17:08

I own 30% of these myself. Oops no, got the decimals wrong it should be .03%, or maybe .003%

[tradermichael] 20/10/2017 15:53

Thanks, anhar ... that explains it nicely!

[anhar] 20/10/2017 15:35

The explanation for the ostensibly very low institutional holdings is that the evidence presented covers only US inst. holders who are only a small minority of the total inst. holders since GSK is a Brit company. So that report is worthless for identifying the overall level of institutional trading in GSK shares and therefore useless for drawing any conclusions from it.

Not that knowing inst. trading is of any use anyway as a guide to the merits of the shares.

[tradermichael] 20/10/2017 14:31

GSK will announce their third quarter 2017 results on Wednesday 25 October at 12pm BST (7am EST) - you can register for the webcast on

[alphorn] 20/10/2017 12:45

...must be!

[grahamite2] 20/10/2017 11:56

Blackrock alone holds 6.66%. There is a typo, obviously.

[mattboxy] 20/10/2017 11:51

So little private investors own 90%+ of glaxo !! Something very wrong there!

[tradermichael] 20/10/2017 11:36

The figures are as reported in the last quarter's SEC 13F filings

[grahamite2] 20/10/2017 11:31

Institutions own 09.34% of GlaxoSmithKline plc (GSK)’s shares.

I find that very hard to believe. Surely something like 69.34% or 79.34% is more likely?

[dr biotech] 20/10/2017 09:05

There are a lot of automated websites about giving the sort of info above. I find it makes it harder to get proper news. Many seem to describe the daily share price movements..I wonder how they make money

[tradermichael] 20/10/2017 09:01

Never had the jab .... never had 'flu.

Anyway,

Recent insider trends for GlaxoSmithKline plc (NYSE:GSK) have caught the attention of investors. Patters in insider activity can help analysts formulate an outlook for a stock. In the case of GSK, the data has a lot to say about how the stock might perform going forward.

Institutions own 09.34% of GlaxoSmithKline plc (GSK)’s shares. The total value of these holdings, in millions, is $9,389. Among active positions in the latest quarter, 343 holders increased their positions by a total of 22.86 million shares, 332 holders decreased the positions by a total of 14.11 million shares, and 161 holders held their positions. This works out to a net increase in ownership of 8.74 million shares, and suggests that institutions are feeling bullish about the stock.

Among new and sold out positions, 64 holders initiated new positions by a total of 2.82 million shares and 62 holders exited their positions by a total of 1.4 million shares. This nets out to an increase of 1.41 million shares and is a bullish sign for GSK.

[romeike] 19/10/2017 19:14

Had the jab every year for six years, not had flu since

[ny boy] 19/10/2017 16:13

Heading to test 1550p, then onwards & upwards

[essentialinvestor] 19/10/2017 12:37

Had the flu jab. Hoping the outlook this winter is better than some anticipate.

NHS workers now need to sign a form giving reasons, if they refuse vaccination.